#AHA20 – Randomized trial: In patients with atrial fibrillation and a bioprosthetic mitral valve, Rivaroxaban (20 mg) was noninferior to Warfarin (INR 2-3) for death, MACE, or major bleeding at 12 months

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF – American Heart Association

Commentaries: Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib – TCTMD AND Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation – RIVER – American College of Cardiology AND Rivaroxaban Noninferior to Warfarin for Atrial Fibrillation in Patients with Bioprosthetic Mitral Valves – NEJM Journal Watch

Commentary on Twitter

In a trial comparing rivaroxaban with dose-adjusted warfarin, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. #AHA20

— NEJM (@NEJM) November 14, 2020